Japanese
sitemap
contact us
April 9, 2008
NK4 Patented in Japan as a Preventive and Therapeutic Agent for Diseases Associated with Abnormal Angiogenesis.
April 2, 2008
Kringle Awarded NIBIO R&D Promotion Grant for Clinical Development of Human Recombinant HGF for Neurological Disorders.
January 22, 2008
Tripep and Kringle Pharma apply cooperatively for permission to launch a Phase II study of ChronSeal.
Copyright (C)2004 Kringle Pharma, Inc. All rights reserved.
April 9, 2008